Highlights
Revenue
from continuing operations
+4.0%
to R13.0 billion
Normalised EBITDA* from continuing operations of R2.4 billion
Cash generated from
operations of R2.3 billion
Normalised earnings per share (NEPS)*
from continuing operations
–2.4%
to 52.8 cents
Completed disposal of Scanmed for a total cash consideration of R733 million
Strong financial position with
available undrawn facilities of
R6.4 billion
* Non-IFRS measures.